Augmedix(AUGX)

搜索文档
Augmedix(AUGX) - 2020 Q1 - Quarterly Report
2020-05-16 00:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 000-56036 MALO HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) | --- | --- | |--------- ...
Augmedix(AUGX) - 2019 Q4 - Annual Report
2020-03-31 05:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-56036 MALO HOLDINGS CORPORATION (Exact name of registrant as specified in charter) Delaware 83-3299164 (State or other jurisdiction ...
Augmedix(AUGX) - 2019 Q3 - Quarterly Report
2019-11-14 06:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 000-56036 MALO HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) | --- | --- | |----- ...
Augmedix(AUGX) - 2019 Q2 - Quarterly Report
2019-08-14 05:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 000-56036 MALO HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) | --- | --- | |---------- ...
Augmedix(AUGX) - 2019 Q1 - Quarterly Report
2019-05-20 22:22
公司“新兴成长公司”身份相关 - 公司将保持“新兴成长公司”身份直至最早出现以下情况之一:财年营收超10.7亿美元、三年发行超10亿美元非可转换债券、首次公开发行普通股证券后第五个财年结束日、非关联股东持有的普通股市值在最近完成的第二个财季最后一个工作日超7亿美元[34] - 公司作为“新兴成长公司”,选择使用JOBS法案规定的延长过渡期来遵守新的或修订的会计准则,财务报表可能与遵循上市公司生效日期的公司不可比[33][51] 财务数据关键指标变化 - 截至2019年3月31日,公司现金为2503美元,总资产为3679美元,均为现金;而2018年12月31日总资产为25美元,为股票认购应收款[38][44] - 截至2019年3月31日,公司流动负债总计46169美元,包括应计费用和应付关联方款项;2018年12月31日总流动负债为34548美元,同样由应计费用和应付关联方款项构成[44] - 2019年第一季度,公司经营活动净现金使用量为7346美元,融资活动提供的净现金为11025美元,现金净增加3679美元[45] - 2019年第一季度,公司净亏损7967美元,包括法律、会计、审计等专业服务费、一般及行政费用和利息费用[48] 本票相关情况 - 2018年12月27日,公司向股东兼董事Mark Tompkins发行本票,年利率6%,违约后年利率18%;截至2019年3月31日,本票欠款46169美元,含应计利息644美元[46] 公司业务活动情况 - 公司自成立以来未开展任何产生现金流的业务活动,未来十二个月预计产生提交报告和进行收购相关成本[37] - 公司目前未与任何方达成最终协议,也未与潜在业务合并候选方进行具体讨论[42] 公司性质及目标 - 公司作为“空白支票”公司和“壳公司”,无意在成功完成业务合并前促使证券市场发展[31]